Olympus Corporation (OLYMY)
OTCMKTS · Delayed Price · Currency is USD
12.08
+0.20 (1.68%)
Aug 1, 2025, 9:30 AM EDT
Bally's Revenue
In the fiscal year ending March 31, 2025, Olympus had annual revenue of 997.33B JPY with 6.53% growth. Olympus had revenue of 272.11B in the quarter ending March 31, 2025, with 4.46% growth.
Revenue
997.33B JPY
Revenue Growth
+6.53%
P/S Ratio
2.08
Revenue / Employee
34.04M JPY
Employees
29,297
Market Cap
13.86B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 997.33B | 61.12B | 6.53% |
Mar 31, 2024 | 936.21B | 54.29B | 6.16% |
Mar 31, 2023 | 881.92B | 13.06B | 1.50% |
Mar 31, 2022 | 868.87B | 138.32B | 18.93% |
Mar 31, 2021 | 730.54B | -66.87B | -8.39% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |